Summary: The ability to risk stratify a patient population to inform population level interventions is key to efficient, high quality, measurement-based care. Current methodologies focus predominantly on validated assessments alone, without consideration of other qualitative measures of symptom impact on functionality. This study details the development of the NeuroFlow Severity Score (NFSS) and evaluates its utility for population level risk stratification when compared to the Personal Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder-7 (GAD-7), and expert clinician review.  Based on over 35,000 NeuroFlow users, the NFSS demonstrates the simultaneous credibility and clinical validity of a comprehensive single risk index while reducing effort and burden for clinicians. 

Stats at a glance: 

• A strong correlation between NFSS and PHQ-9 (r = 0.74, p < 0.001) and GAD-7 (r = 0.80, p < 0.001)
• A strong positive correlation between the NFSS and expert panel clinical assessments (r = 0.80-0.84, p < 0.001)
• The inclusion of self reported and engagement metrics provides evidence of the utility of the NFSS in identifying at-risk individuals otherwise unidentified by the PHQ-9 alone

Summary: The need to effectively scale Jefferson’s Behavioral Health Integration program required an additional layer of technology to reduce administrative burden while increasing the reach and impact of care teams. With this in mind, Jefferson Health partnered with NeuroFlow, giving clinicians the tools and data to effectively engage patients remotely with customized resources to support their health journey.

Stats at a glance:

• 34% decrease in ED visits for patients using NeuroFlow (p < 0.05)
• 19% increase in screening compared to PHQ9 data in EHR alone
• 82% of patients reported improvement in anxiety or depression symptoms